Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 23:11:3197-3213.
doi: 10.2147/CMAR.S180724. eCollection 2019.

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

Tristan Knight  1   2 , Holly Edwards  3   4 , Jeffrey W Taub  1   2   4 , Yubin Ge  2   3   4
Affiliations

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

Tristan Knight et al. Cancer Manag Res. .

Abstract

Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) in adult patients aged 75 years or older, or otherwise unable to tolerate intensive induction chemotherapy, in combination with either hypomethylating agents or low-dose cytarabine. In this review article, we discuss venetoclax's mechanism of action, in relation to both the BCL-2 protein family in general and BH3-mimetic activity in particular. We then outline the pharmacological advances that preceded and facilitated its development, as well as providing an overview of key preclinical and clinical studies which lead to its use first in chronic lymphoid leukemia (CLL), then in small lymphocytic leukemia (SLL), and subsequently in AML. Finally, we seek to offer an overview of the challenges and opportunities encountered as venetoclax moves into more widespread use, including its use and activity against leukemia initiating cells and oxidative phosphorylation.

Keywords: ABT-199; BCL-2 inhibitor; BH3-mimetic; acute myeloid leukemia; apoptosis; venetoclax.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475–486. doi:10.1200/JCO.2010.30.2554 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA-Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442 - DOI - PubMed
    1. Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627–1635. doi:10.1182/blood-2016-10-696039 - DOI - PubMed
    1. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. doi:10.1016/S0140-6736(18)31041-9 - DOI - PMC - PubMed
    1. Click ZR, Seddon AN, Bae YR, Fisher JD, Ogunniyi A. New food and drug administration-approved and emerging novel treatment options for acute myeloid leukemia. Pharmacotherapy. 2018;38(11):1143–1154. doi:10.1002/phar.2180 - DOI - PubMed